Pharmafile Logo
Pharmafocus logo
Advanced Search

Eisai

Showing 15 posts of 111 posts found.

pharmafocus_dec_2018_cover

The December issue of Pharmafocus is available to read online now!

December 12, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Eisai, GSK, Gilead, Mundipharma, Pharmafocus, mesothelioma, pharma

The December edition of Pharmafocus is live and available to read online now!Brexit continues to dominate the headlines inside and …

News
eisa0001

Eisai’s Lenvima wins over NICE in liver cancer in just three months

November 9, 2018
Medical Communications, Sales and Marketing Cancer, Eisai, Lenvima, Levantinib, NHS, NICE, UK, liver cancer, pharma

Eisai has revealed that its multireceptor Tyrosine Kinase Inhibitor Lenvima (lenvatinib) has been recommended by NICE, meaning it can now …

News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

August 31, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Eisai, Medicare, Novartis, UK, brexit, generics, king bio, pharma, top ten

Eight months of 2018 down – where has the year gone? As we move from August into September, and a …

News
eisa0008_web

Eisai’s weight loss drug lorcaserin found safe in major study

August 28, 2018
Manufacturing and Production, Research and Development, Sales and Marketing Eisai, lorcaserin, safety, study, weight loss

Eisai’s weight loss drug lorcaserin does not increase people’s risk of major cardiovascular events according to a study of 12,000 …

News
394px-ad_versus_co

Eisai and Biogen’s Alzheimer’s drug slows progression in Phase 2 trials

July 26, 2018
Research and Development Alzheimer's disease, BAN2401, Biodgen, Eisai, phase 2, research

An experimental drug developed by the Massachusetts-based multinational Biogen and their Japanese partner Eisai has been shown to significantly slow …

News
eisa0003

Eisai forms partnership to find new tuberculosis treatment

April 13, 2018
Medical Communications, Research and Development Colorado State University, Eisai, broad institute, pharma, tuberculosis, university of chicago

Eisai has teamed up with the Broad Institute, the Mycobacteria Research Laboratories at Colorado State University and the University of …

News
shutterstock_273326141

Eisai and MSD team up to combine Lenvima and Keytruda in cancer

March 8, 2018
Sales and Marketing Cancer, Eisai, Kidney cancer, Lenvima, MSD, Merck, keytruda, pharma

Pharma heavyweights MSD (Merck) and Eisai have announced they are to join forces to develop and commercialise the latter’s tyrosine …

News

NICE rejects Eisai’s Halaven in earlier setting for metastatic breast cancer

February 22, 2018
Sales and Marketing Brest cancer, Cancer, Eisai, Halaven, NICE, pharma

NICE has published its decision not to recommend Eisai’s Halaven (eribulin) in the treatment of locally advanced or metastatic breast …

News

NICE recommends thyroid cancer drug trio for NHS use

February 20, 2018
Manufacturing and Production, Sales and Marketing Bayer, Cancer, Cometriq, Eisai, Lenvima, NICE, Nexavar, ipsen, pharma, thyroid cancer

NICE has announced its decision to recommend that three separate treatments for thyroid cancer should be made available for use …

News
nerve-cell-2213009_960_720

Eisai and Biogen Alzheimer’s drug stumbles at P2

December 21, 2017
Medical Communications, Research and Development Biogen, Eisai, biotech, drugs, pharma, pharmaceutical

Only a few months ago, it was announced that Eisai had decided to opt into the development process of BAN2401. …

News

NICE refuses Eisai’s breast cancer drug in new indication

November 28, 2017
Manufacturing and Production, Sales and Marketing Cancer, Eisai, Halaven, NICE, breast cancer, pharma

NICE has announced that it has rejected Eisai’s Halaven (eribulin) through draft guidance advising not to use the drug in …

News
shutterstock_38078521

Real-world data prove efficacy of Eisai and Bial’s epilepsy treatment

September 6, 2017
Research and Development Bial, Eisai, Zebinix, epilepsy, pharma

Bial and Eisai have released real-world data which support the efficacy of Zebinix (eslicarbazepine acetate) in the treatment of partial-onset …

News

European approval for novel Eisai epilepsy monotherapy

May 23, 2017
Research and Development, Sales and Marketing Bial, Eisai, Zebinix, epilepsy

Eisai and Bial have revealed that their drug Zebinix (eslicarbazepine acetate) has been awarded marketing authorisation by the European Commission …

News
access_accelerated

22 pharma companies join forces for global non-communicable disease initiative

January 18, 2017
Research and Development BMS, Celgene, Eisai, Eli Lilly, GSK, J&J, JJ, MSD, Merck, Novartis, Pfizer, Roche, Sanofi, Takeda

The World Economic Forum Annual Meeting in Switzerland has seen the launch of Access Accelerated, a global initiative consisting of …

News
eisai_halaven_eribulin_web

Eisai & Clinigen to bring breast cancer drug to South Africa

December 1, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Clinigen, Eisai, South Africa, breast cancer

Eisai and Clinigen have formed a collaboration to deliver the former’s cancer treatment Halaven (eribulin) to women in South Africa …

News

Latest content

GSK shares data from global shingles survey

December 1, 2023

AbbVie to acquire ImmunoGen for approximately $10.1bn

December 1, 2023

FDA accepts NDA for Karuna’s schizophrenia treatment

November 30, 2023

Vivos Therapeutics gains FDA 510(k) clearance for sleep apnea treatment device

November 30, 2023

Tolremo doses first patient in phase 1 trial for drug to combat transcriptional cancer drug resistance

November 29, 2023